US pharma major Eli Lilly (NYSE: LLY) has announced positive results from the Phase III REGARD trial of ramucirumab (IMC-1121B) as a single agent in patients with advanced gastric cancer who have had disease progression after initial chemotherapy were published today in The Lancet. 3 October 2013
The UK’s drugs watchdog, the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending Swiss drug major Roche’s MabThera as a National Health Service option for treating some adults with the rare autoimmune condition, anti-neutrophil cytoplasmic antibody-associated vasculitis. 3 October 2013
Swiss drug major Roche has provided an update from its leading late-stage pipeline comprising 10 new molecular entities in key therapeutic areas: oncology, immunology and ophthalmology and neuroscience at a London, UK, investor event. 2 October 2013
Kissei Pharmaceutical and JCR Pharmaceuticals have announced the conclusion of a collaborative R&D agreement for a biosimilar to a long-acting erythropoiesis stimulating agent, darbepoetin alfa. 1 October 2013
Gliknik has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, which is designed to replace and improve on pooled human intravenous immunoglobulin. 30 September 2013
ProStrakan has started the European Union roll-out of its transdermal patch Sancuso for the prevention of chemotherapy-induced nausea and vomiting. 30 September 2013
Thousands of cancer patients in England will get life-saving drugs thanks to an extra £400 million invested in the Cancer Drugs Fund. 30 September 2013
Roche presented new results from a trial of an investigational antibody which have shown encouraging responses in patients who are smokers or former smokers. 30 September 2013
Boehringer Ingelheim has been granted marketing authorization from the European Commission for Giotrif for non-small cell lung cancer. 27 September 2013
Drugs watchdog the National Institute for Health and Care Excellence (NICE) is currently considering if five ovarian cancer treatments work well enough to be funded by the NHS in the UK. 27 September 2013
US drug major Eli Lilly has announced top-line results from a global Phase III study of ramucirumab in advanced gastric cancer, but has revealed disappointing results for a Phase III study of the drug in metastatic breast cancer. 26 September 2013
The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra and Rituxan. 26 September 2013
Diagnostic testing provider Genomic Health has announced that the UK’s National Institute for Health and Care Excellence has issued its final guidance recommending Oncotype DX as a multi-gene breast cancer test. 26 September 2013
Merck Serono will continue clinical development of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide under a new Phase III trial called START2 for patients with Stage III non-small cell lung cancer. 25 September 2013
US drug developer Inovio Pharmaceuticals has demonstrated the success of its new DNA plasmid technology in generating therapeutic monoclonal antibodies. 25 September 2013
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended German drug major Bayer’s (BAYN: DE) radium Ra 223 dichloride (radium-223) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer. 20 September 2013
The cancer drug Kadcyla (trastuzumab emtansine) has today received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of people with HER2-positive metastatic breast cancer. 20 September 2013
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024